TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03398148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: placebo for risankizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: placebo for risankizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab SC
Description: risankizumab subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab SC
Description: risankizumab subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab SC
Description: risankizumab subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab SC
Description: risankizumab subcutaneous (SC) injection
Study: NCT02882282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01662427

Intervention type: OTHER
Intervention: Questionaire to assess Noctural Parkinson's Disease Symptoms
Description: Questionaire to assess Noctural Parkinson's Disease Symptoms and quality of life
Study: NCT00559910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: PH-797804 at four dose levels

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03442127

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CaringGuidance™ After Breast Cancer Diagnosis
Description: Web-based, psychoeducational, self-management tool
Study: NCT00911924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Glaukos iStent, medication
Study: NCT02606773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: Ascorbic acid in different ways and doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: Ascorbic acid in different ways and doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascorbic acid in different ways and doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascorbic acid in different ways and doses
Study: NCT02848885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active TDCS
Description: Participants will receive active tDCS stimulation.
Study: NCT01656603

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: unlicensed CBU
Description: infusion of unlicensed cord blood units
Study: NCT03565861

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP10679
Description: NP10679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP10679
Description: NP10679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP10679
Description: NP10679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP10679
Description: NP10679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP10679
Description: NP10679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP10679
Description: NP10679
Study: NCT00107380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tositumomab and iodine I 131 tositumomab
Study: NCT00548275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Sexual Risk Management
Description: management of sexual risk

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Sexual Risk Management
Description: management of sexual risk
Study: NCT02078310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007
Description: ITI-007 for Part 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ITI-007 for Part 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007
Description: ITI-007 for Part 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Part 2
Study: NCT06781164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: Recording of the ear of each patient with an ear problem
Study: NCT02848885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham TDCS
Description: Participants will receive sham tDCS stimulation
Study: NCT04388657

Intervention type: DIAGNOSTIC_TEST
Intervention: Echo-Doppler
Description: Utrasound Doppler of the lower limbs
Study: NCT00789776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation
Study: NCT01232244

Intervention type: OTHER
Intervention: GLP-1 infusion
Description: 1 pmol/kg/min

Intervention type: OTHER
Intervention: Glucagon infusion
Description: 3ng/kg/min

Intervention type: OTHER
Intervention: Oxyntomodulin infusion
Description: 3 pmol/kg/min

Intervention type: OTHER
Intervention: GLP-1 and glucagon infusion
Description: 1 pmol/kg/min 3 ng/kg/min

Intervention type: OTHER
Intervention: Placebo
Description: NaCl 9 g/L infusion
Study: NCT04345133

Intervention type: DEVICE
Group type: OTHER
Intervention: Dental Implants Insertion Drilling Sequence
Description: Drilling sequence protocol to insert immediate Dental Implants at the Maxilla.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implants Insertion Drilling Sequence
Description: Drilling sequence protocol to insert immediate Dental Implants at the Maxilla.
Study: NCT03053245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Critical Care Program
Description: The m-CCRP revolves around the central figure of a care coordinator who will organize and align recovery resources. The care coordinator is a registered nurse whose scope of practice includes health coaching, case managing, community organizing, and nursing care provider. The m-CCRP support team will consist of a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), an ICU collaborative care nurse (Dr. Lasiter), and a psychologist (Dr. Unverzagt). This team will meet weekly with the care coordinator. Drs. Khan and Boustani will be accessible to the coordinator through phone or pager at all times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Patients in this group will receive regular wellness calls from the research team.
Study: NCT02625298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Description: Apical thirds of the root canals obturated with ProRoot MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK USA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MTA+ Cerkamed
Description: Apical thirds of the root canals obturated with MTA + (Cerkamed, Stalowa Wola, Poland).
Study: NCT01662011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mode of neurally adjusted ventilatory assist
Description: patients ventilated with the mode of neurally adjusted ventilatory assist after corrective open-heart surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mode of pressure support ventilation
Description: Patients ventilated with the mode of pressure support ventilation after corrective open-heart surgery
Study: NCT03695354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration plus conventional therapy
Description: Subjects enrolled in whole body vibration training group are exposed to side-to-side alternating vertical sinusoidal vibration. Galileo system(Novotec Medical GmbH, Pforzheim, Germany) is used to training. Frequency of whole body vibration is 12Hz and amplitude is 4mm. After 10 minutes of vibration training, subjects rest 3 minutes. Then, additional 10 minutes of training will be given.~conventional physical therapy is consisted of passive range of motion exercise and walking exercise.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional physical therapy is consisted of passive range of motion exercise and walking exercise.
Study: NCT00178711

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermia
Description: Induction of moderate hypothermia to 33 degrees celsius, within 2.5 hours from time of injury and maintained for 48 hours
Study: NCT04129528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CFZ533
Description: First dose is administered via intravenous infusion, subsequent doses are administered subcutaneously.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for active drug
Study: NCT05464485

Intervention type: PROCEDURE
Intervention: ACL hamstring reconstructions using semitendinosus (ST) tendon only
Description: ACL reconstruction with a ST tendon graft received a reconstruction according to the Tape Locking Screw technique (FH Industrie, Quimper, France) with a dedicated interference screw

Intervention type: PROCEDURE
Intervention: ACL hamstring reconstructions using semitendinosus and gracilis (ST/G) tendon
Description: ACL reconstruction with a ST/G tendon graft received a reconstruction with the anteromedial portal technique with endobutton fixation (Smith \& Nephew, London, UK).
Study: NCT01943539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-typical controls and ADHD will receive EVO game play.
Description: EVO mobile video application
Study: NCT01196910

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treatment by HLPFC coil
Description: DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel).~Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase.
Study: NCT00382473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program - 8 weeks
Description: No drugs. Regular aerobic exercise in structured prescription format
Study: NCT01196910

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: treatment by HLPFC coil
Description: DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel).~Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase.
Study: NCT03927027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosulfan Blue
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosulfan Blue
Description: Given SC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Lymph Node Dissection
Description: Undergo ALND

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection
Description: Undergo ALND

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mapping
Description: Undergo ARM
Study: NCT04311476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy
Description: Evaluate Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates
Study: NCT03927027

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02849106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy to obtain a chemogram
Description: All patients enrolled will have biopsies (on primary tumor or on a metastasis) before treatment in order to obtain a chemogram by ex vivo 3D culture cells
Study: NCT03927027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04311476

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodiun Chloride
Description: 0.9% Sodiun Chloride in control group
Study: NCT02468089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbepenem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbepenem
Study: NCT03927027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03522246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral rucaparib will be administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral rucaparib will be administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral rucaparib will be administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV nivolumab will be administered once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV nivolumab will be administered once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV nivolumab will be administered once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo tablets will be administered twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets will be administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV Infusion
Description: IV placebo will be administered once every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV Infusion
Description: IV placebo will be administered once every 4 weeks
Study: NCT02468089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMCSF (of Granulocyte-Monocyte Colony-Stimulating Factor) .
Study: NCT01738139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study: NCT03760640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study: NCT06627634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastatectomia and standard treatment for resectable disease.
Description: Rather than palliative chemotherapy, the intervention offered to participants is preoperative chemotherapy, resection of primary tumour and metastatectomia of oligometastatic spread to the liver. If fit for post-operative chemotherapy, this is offered as well.
Study: NCT02258035

Intervention type: OTHER
Intervention: Blood draw
Description: Sampling of 100-150 ml of blood

Intervention type: OTHER
Intervention: Blood draw
Description: Sampling of 100-150 ml of blood

Intervention type: OTHER
Intervention: Blood draw
Description: Sampling of 100-150 ml of blood
Study: NCT04384224

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: use disposable sterile steel needles to insert to the acupuncture point

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: use disposable sterile steel needles to insert to the acupuncture point

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: use disposable sterile steel needles to insert to the acupuncture point

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: use disposable sterile steel needles to insert to the acupuncture point
Study: NCT03762954

Intervention type: OTHER
Intervention: Neurocognitive function assessment
Description: Neurocognitive function will be assessed via a phone battery derived from standard cognitive tests proven feasible and valid to assess memory, attention, reasoning, and executive functioning. Functional status will also be assessed via phone. The duration of time required for the patient to complete telephone interview for neurocognitive and functional assessment will be approximately 45 minutes per time point.
Study: NCT02471807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards FORMA Tricuspid Transcatheter Repair System
Study: NCT03898908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: Encorafenib 75mg and 50mg (capsules) for a 450mg daily for oral administration during 56 days and after local radiation treatment.~If no progression of disease progression (PD) is reported, treatment will continue until PD, unacceptable toxicity or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Binimetinib 15mg (tablets) for a 45mg/12 hours for oral administration during 56 days and after local radiation treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole brain radiation therapy
Description: The whole brain planning target volume (PTV) will receive 30 Gy in 10 fractions.~Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery/stereotactic radiosurgery
Description: Dose selection must be based on previously published Radiation Therapy Oncology Group (RTOG) data, with dose modification left up to the treating physician. The total dose will depend on the size of the metastatic lesion(s) and proximity to critical structures.~Suggested doses are as follow: 1 fraction x 15-25 Gy; 3 fractions x 9-11 Gy; 5 fractions x 6-7 Gy; or 6 fractions x 5-6 Gy.~For GTV \> 20 mm hypofractionated stereotactic radiotherapy could be preferred. Treatment will be delivered once daily, alternate-day, 3 fractions per week.
Study: NCT02726841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open thoracoabdominal aortic repair + abdominal stenting
Description: Thoracoabdominal aortic dissection (TAAD) repair + bare aortic stent (Djumbodis) implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic thoracoabdominal aortic repair
Description: Thoracoabdominal aortic dissection (TAAD) repair
Study: NCT04121533

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement for vitamin D (cholecalciferol), glucosamine sulfate, and omega-3 fatty acids. Supplement was taken orally every day for 84-days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol)
Description: Vitamin D (cholecalciferol). Supplement was taken orally every day for 84-days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol)
Description: Vitamin D (cholecalciferol). Supplement was taken orally every day for 84-days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate and omega-3 fatty acids
Description: Glucosamine sulfate and omega-3 fatty acids supplement was taken orally every day for 84-days.
Study: NCT00685334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Participants will take olanzapine daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Participants will take aripiprazole daily for 12 weeks.
Study: NCT04468282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VGB-ST
Description: Single oral administration of 500 mg VGB-ST

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGB-ST
Description: Single oral administration of 500 mg VGB-ST
Study: NCT00158925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EASYTRAK EPI lead
Description: EASYTRAK EPI lead
Study: NCT02934334

Intervention type: OTHER
Intervention: Observational
Study: NCT00529191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months
Study: NCT00619541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusional 5-Fluorouracil
Description: 5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Bay 43-9006)
Description: Sorafenib 400 mg bid orally continuously. Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease.
Study: NCT02500030

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glossopharyngeal Breathing
Description: Glossopharyngeal Breathing is a type of lung recruitment technique where the patients take a multiple inssuflations with their glossopharyngeal muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air Stacking
Description: Air Stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.